The World Health Organization (WHO) estimates that every $1 invested in treating depression results in a $4 return on productivity. By helping employees reduce their depressive symptoms, deprexis® enables employers to reduce direct and indirect losses due to workplace depression.
By integrating directly into the care of your employee’s physician, deprexis® can help reduce your medical expenses on employee therapy sessions.
Every employer and employee is different. That’s why deprexis® is highly personalized to specific needs and easily accessible on all internet-connected devices for independent use that integrates into everyday life.
Your employee-benefit package is instantly upgraded with deprexis®, empowering you to play a key role in nurturing the mental health of your employees.
RCTs demonstrate deprexis®’ effectiveness, safety and suitability.
Nine independent studies conducted with deprexis® have demonstrated its effectiveness as a standalone treatment and have confirmed the increase in benefits when deprexis® is added to existing care plans.
Depression is especially prevalent in patients with severe medical conditions and disorders. deprexis® has been shown to effectively treat depression as a comorbidity of epilepsy, multiple sclerosis and gambling disorder.
A study of 3,805 participants demonstrated using deprexis® significantly reduces the cost of treating depression for health insurers, while simultaneously reducing depressive symptoms and increasing quality of life in patients.
Gräfe et al. (2017)
Multiple meta-analyses and systematic reviews have confirmed the scientific evidence gathered in 13 RCTs that deprexis® is an effective treatment for depression.
USA: University of Texas, Austin; Cedars Sinai Medical Center Los Angeles; University of Massachusetts Medical School
SWEDEN: The Karolinska Institute; Linkoping University
GERMANY: Charite Universitätsmedizin Berlin; Universität Trier; Universität Tübingen
UK: University of Cambridge; Kings College London; City University, London
FUNDING PARTNERS: the U.S. department of veteran affairs, the U.S. national multiple sclerosis society, the European Union, the European Commission, the German ministry of health, and the Brain and Behavior Research Foundation, the German Association of Psychotherapists (DPTV), major German health insurance companies and several other research centers, universities and hospitals across Europe, the U.S. and other regions.